Lag3 blockade enhances the anti-tumor effect of dual GITR agonism and PD-1 blockade in a preclinical melanoma model

被引：0
|
作者：
Maniyar, Rachana R.
Elhanati, Yuval
Mangarin, Levi
Marouf, Yacine
Ahmed, Ashley
Greenbaum, Benjamin
Wolchok, Jedd
Merghoub, Taha
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4034
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
    Yinli Yang
    Ling Li
    Zhansheng Jiang
    Bin Wang
    Zhanyu Pan
    Cancer Immunology, Immunotherapy, 2020, 69 : 2523 - 2532
  • [32] PD-1 BLOCKADE ENHANCES THE EFFICACY OF ELOTUZUMAB IN MOUSE TUMOR MODELS
    Bezman, N.
    Jhatakia, A.
    Kearney, A.
    Brender, T.
    Maurer, M.
    Sum, C.
    Lei, M.
    Waggie, K.
    Postelnek, J.
    Henning, K.
    Jenkins, M.
    Rogers, A.
    Neeson, P.
    Korman, A.
    Robbins, M.
    Graziano, R.
    HAEMATOLOGICA, 2016, 101 : 161 - 162
  • [33] Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
    Yang, Yinli
    Li, Ling
    Jiang, Zhansheng
    Wang, Bin
    Pan, Zhanyu
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (12) : 2523 - 2532
  • [34] PD-1 blockade enhances elotuzumab efficacy in mouse tumor models
    Bezman, Natalie A.
    Jhatakia, Amy
    Kearney, Alper Y.
    Brender, Ty
    Maurer, Mark
    Henning, Karla
    Jenkins, Misty R.
    Rogers, Amy J.
    Neeson, Paul J.
    Korman, Alan J.
    Robbins, Michael D.
    Graziano, Robert F.
    BLOOD ADVANCES, 2017, 1 (12) : 753 - 765
  • [35] Rovalpituzumab tesirine enhances the anti-tumor efficacy of PD-1 blockade in a murine model of small cell lung cancer with endogenous 0113 expression
    Vitorno, Philip M.
    Chuang, Chen-Hua
    Moore, Christine
    Turan, Tolga
    Ferrando, Ronald
    Nichols, Aaron
    Madhavan, Shravanthi
    Saunders, Laura R.
    CANCER RESEARCH, 2019, 79 (13)
  • [36] SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
    Zhao, M.
    Guo, W.
    Xu, Q.
    Sun, Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1856 - 1856
  • [37] SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
    Zhao, Mingxia
    Guo, Wenjie
    Wu, Yuanyuan
    Yang, Chenxi
    Zhong, Liang
    Deng, Guoliang
    Zhu, Yuyu
    Liu, Wen
    Gu, Yanhong
    Lu, Yin
    Kong, Lingdong
    Meng, Xiangbao
    Xu, Qiang
    Sun, Yang
    ACTA PHARMACEUTICA SINICA B, 2019, 9 (02) : 304 - 315
  • [38] SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
    Mingxia Zhao
    Wenjie Guo
    Yuanyuan Wu
    Chenxi Yang
    Liang Zhong
    Guoliang Deng
    Yuyu Zhu
    Wen Liu
    Yanhong Gu
    Yin Lu
    Lingdong Kong
    Xiangbao Meng
    Qiang Xu
    Yang Sun
    ActaPharmaceuticaSinicaB, 2019, 9 (02) : 304 - 315
  • [39] RETRACTED ARTICLE: Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
    Asal Barshidi
    Vahid Karpisheh
    Fatemeh Karimian Noukabadi
    Fariba Karoon Kiani
    Mohammad Mohammadi
    Negin Afsharimanesh
    Farbod Ebrahimi
    Seyed Hossein Kiaie
    Jamshid Gholizadeh Navashenaq
    Mohammad Hojjat-Farsangi
    Naime Majidi Zolbanin
    Ata Mahmoodpoor
    Hadi Hassannia
    Sanam Nami
    Pooya Jalali
    Reza Jafari
    Farhad Jadidi-Niaragh
    Pharmaceutical Research, 2022, 39 : 1851 - 1866
  • [40] Retraction Note: Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
    Asal Barshidi
    Vahid Karpisheh
    Fatemeh Karimian Noukabadi
    Fariba Karoon Kiani
    Mohammad Mohammadi
    Negin Afsharimanesh
    Farbod Ebrahimi
    Seyed Hossein Kiaie
    Jamshid Gholizadeh Navashenaq
    Mohammad Hojjat-Farsangi
    Naime Majidi Zolbanin
    Ata Mahmoodpoor
    Hadi Hassannia
    Sanam Nami
    Pooya Jalali
    Reza Jafari
    Farhad Jadidi-Niaragh
    Pharmaceutical Research, 2024, 41 : 407 - 408
12345